Chordia Therapeutics Inc.
public_traded
Chordia Therapeutics Inc. is publicly traded on JPX under ticker 190A.T.
Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporate value, such as out-licensing and joint development and sales.